Pliant Therapeutics, Inc. (PLRX) vs Xilio Therapeutics, Inc. (XLO)

A side-by-side comparison of Pliant Therapeutics, Inc. and Xilio Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — PLRX vs XLO

growth of $100 · dividends reinvested · last 5y
PLRX -94.0% (-43.1%/yr)XLO -95.9% (-47.3%/yr)PLRX compounded faster over this window
050100150200Start $10020222023202420252026$6$4
PLRX XLO

PLRX vs XLO: by the numbers

  • •PLRX is the larger company ($63M vs $60M market cap).
  • •Both run net losses; PLRX's is the smaller (0.00% vs -34.06% net margin).

Metrics side by side

Valuation

MetricPLRXXLO
P/S ratioN/A0.94
P/B ratio0.430.84

Profitability

MetricPLRXXLO
Gross margin0.00%99.46%
Operating margin0.00%-95.92%
Net margin0.00%-34.06%
ROE-62.81%-30.21%
ROIC-56.22%-26.13%

Growth (annualized)

MetricPLRXXLO
Total return CAGR (5Y)-43.17%N/A

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.